Moderna reinvests cost savings in cancer therapies, staking its post-pandemic transition on clinical development and manufacturing
As its personalized cancer vaccine moves toward launch preparations, Moderna is choosing to invest cost savings in oncology research and development. The next test is turning clinical results into approvals and reliable supply to support a new round of growth.